Ribavirin Priming Improves the Virological Response to Antiviral Treatment in Transplanted Patients with Recurrent Hepatitis C: A Pilot Study | Zendy

Manuela Merli | Zendy; V. Giannelli | Zendy; Federica Gentili | Zendy; M. Giusto | Zendy; Maurizio Simmaco | Zendy; Luana Lionetto | Zendy; Stefano Ginanni Corradini | Zendy; Elisa Biliotti | Zendy; A.F. Attili | Zendy; Massimo Rossi | Zendy; Gloria Taliani | Zendy

Open Access

Ribavirin Priming Improves the Virological Response to Antiviral Treatment in Transplanted Patients with Recurrent Hepatitis C: A Pilot Study

Author(s) -

Manuela Merli,

V. Giannelli,

Federica Gentili,

M. Giusto,

Maurizio Simmaco,

Luana Lionetto,

Stefano Ginanni Corradini,

Elisa Biliotti,

A.F. Attili,

Massimo Rossi,

Gloria Taliani

Publication year - 2011

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp1834

Subject(s) - ribavirin , tolerability , medicine , gastroenterology , hepatitis c , pegylated interferon , combination therapy , transplantation , liver transplantation , hepatitis c virus , immunology , adverse effect , virus

Patients with hepatitis C recurrence after liver transplantation represent a clinical challenge. Antiviral treatment in transplant patients has usually poor tolerability and limited efficacy, with a mean sustained virological response (SVR) of 30%. Our pilot study was aimed at evaluating whether 8-week ribavirin pre-treatment could increase either adherence or antiviral effect of a 48-week combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research